BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kotze PG, Ma C, Mckenna N, Almutairdi A, Kaplan GG, Raffals LE, Loftus EV Jr, Panaccione R, Lightner AL. Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis. Therap Adv Gastroenterol 2018;11:1756284818783614. [PMID: 29977340 DOI: 10.1177/1756284818783614] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Conrad MA, Kelsen JR. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies. Curr Gastroenterol Rep 2020;22:36. [PMID: 32542562 DOI: 10.1007/s11894-020-00773-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Battat R, Dulai PS, Jairath V, Vande Casteele N. A product review of vedolizumab in inflammatory bowel disease. Hum Vaccin Immunother 2019;15:2482-90. [PMID: 30897022 DOI: 10.1080/21645515.2019.1591139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
3 Adamina M, Bonovas S, Raine T, Spinelli A, Warusavitarne J, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, Doherty G, El-Hussuna A, Ellul P, Fiorino G, Frei-Lanter C, Furfaro F, Gingert C, Gionchetti P, Gisbert JP, Gomollon F, González Lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Kucharzik T, Lytras T, Maaser C, Magro F, Marshall JK, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Stassen L, Torres J, Uzzan M, Vavricka S, Verstockt B, Zmora O. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. J Crohns Colitis 2020;14:155-68. [PMID: 31742338 DOI: 10.1093/ecco-jcc/jjz187] [Cited by in Crossref: 77] [Cited by in F6Publishing: 61] [Article Influence: 38.5] [Reference Citation Analysis]
4 Hazel K, O'Connor A. Emerging treatments for inflammatory bowel disease. Ther Adv Chronic Dis 2020;11:2040622319899297. [PMID: 32076497 DOI: 10.1177/2040622319899297] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 14.0] [Reference Citation Analysis]
5 Parrish AB, Lopez NE, Truong A, Zaghiyan K, Melmed GY, McGovern DPB, Ha C, Syal G, Bonthala N, Jain A, Landers CJ, Targan SR, Fleshner P. Preoperative Serum Vedolizumab Levels Do Not Impact Postoperative Outcomes in Inflammatory Bowel Disease. Dis Colon Rectum 2021;64:1259-66. [PMID: 34516445 DOI: 10.1097/DCR.0000000000001920] [Reference Citation Analysis]
6 Guo D, Jiang K, Hong J, Zhang M, Shi Y, Zhou B. Association between vedolizumab and postoperative complications in IBD: a systematic review and meta-analysis. Int J Colorectal Dis 2021;36:2081-92. [PMID: 34467414 DOI: 10.1007/s00384-021-04017-2] [Reference Citation Analysis]
7 Law CC, Bell C, Koh D, Bao Y, Jairath V, Narula N. Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. Cochrane Database Syst Rev 2020;10:CD013256. [PMID: 33098570 DOI: 10.1002/14651858.CD013256.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Pfeifer KJ, Selzer A, Whinney CM, Rogers B, Naik AS, Regan D, Mendez CE, Urman RD, Mauck K. Preoperative Management of Gastrointestinal and Pulmonary Medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement. Mayo Clin Proc 2021:S0025-6196(21)00633-9. [PMID: 34736777 DOI: 10.1016/j.mayocp.2021.08.008] [Reference Citation Analysis]